- Home
- NUVL vs CPRI Comparison
NUVL vs CPRI Comparison
Compare NUVL & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- CPRI
- Stock Information
- Founded
- NUVL 2017
- CPRI 1981
- Country
- NUVL United States
- CPRI United Kingdom
- Employees
- NUVL N/A
- CPRI N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- CPRI Apparel
- Sector
- NUVL Health Care
- CPRI Consumer Discretionary
- Exchange
- NUVL Nasdaq
- CPRI Nasdaq
- Market Cap
- NUVL 5.5B
- CPRI 2.2B
- IPO Year
- NUVL 2021
- CPRI 2011
- Fundamental
- Price
- NUVL $84.59
- CPRI $19.17
- Analyst Decision
- NUVL Strong Buy
- CPRI Buy
- Analyst Count
- NUVL 10
- CPRI 11
- Target Price
- NUVL $119.60
- CPRI $21.91
- AVG Volume (30 Days)
- NUVL 569.2K
- CPRI 3.3M
- Earning Date
- NUVL 08-07-2025
- CPRI 08-07-2025
- Dividend Yield
- NUVL N/A
- CPRI N/A
- EPS Growth
- NUVL N/A
- CPRI N/A
- EPS
- NUVL N/A
- CPRI N/A
- Revenue
- NUVL N/A
- CPRI $4,442,000,000.00
- Revenue This Year
- NUVL N/A
- CPRI N/A
- Revenue Next Year
- NUVL N/A
- CPRI $4.55
- P/E Ratio
- NUVL N/A
- CPRI N/A
- Revenue Growth
- NUVL N/A
- CPRI N/A
- 52 Week Low
- NUVL $55.54
- CPRI $11.86
- 52 Week High
- NUVL $113.51
- CPRI $43.34
- Technical
- Relative Strength Index (RSI)
- NUVL 64.78
- CPRI 62.82
- Support Level
- NUVL $78.94
- CPRI $16.22
- Resistance Level
- NUVL $82.45
- CPRI $20.05
- Average True Range (ATR)
- NUVL 2.94
- CPRI 0.69
- MACD
- NUVL 0.41
- CPRI 0.18
- Stochastic Oscillator
- NUVL 98.39
- CPRI 74.79
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. Capri also owns a third brand, Versace, but has agreed to sell it to Prada. John Idol has served as Capri's CEO since 2003.